Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

April 30, 2005

Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
DRUG

Tegaserod

Trial Locations (7)

22031

Metropolitan Research, Fairfax

27157

Department of Internal Medicine - Wake Forest University School of Medicine, Winston-Salem

33024

University Clinical Research, Pembroke Pines

33173

Miami Research Associates, Miami

33426

Consultants for Clinical Research of South Florida, Boynton Beach

45219

Consultants for Clinical Research, Cincinnati

53207

The Wisconsin Center for Advanced Research, Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY